JQEZ5

Key Product Details

Product Description

JQEZ5 is a potent and selective SAM-competitive EZH2 lysine methyltransferase inhibitor (IC₅₀ = 11 nM). Selectively binds EZH2 over a panel of 22 methyltransferases. Reduces global level of the PRC2-associated mark H3K27me3 in K562 cells. Suppresses cell growth in CML cells. Inhibits colony formation of primary human CD34⁺ CML stem/ progenitor cells. Antitumor effects in vivo.

Licensing Information

Sold under license from Dana-Farber Cancer Institute.

Product Specifications for JQEZ5

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for JQEZ5

The following data is based on the product molecular weight 542.69.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.2 mM	9.21 mL	46.07 mL	92.13 mL
1 mM	1.84 mL	9.21 mL	18.43 mL
2 mM	0.92 mL	4.61 mL	9.21 mL
10 mM	0.18 mL	0.92 mL	1.84 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Frankel Developing EZH2-targeted therapy for lung cancer. Cancer Discov. 2016 PMID: 27587466
• Zhang Oncogenic deregulation of EZH2 as an opportunity for targeted therapy in lung cancer. Cancer Discov. 2016 PMID: 27312177
• Xie Chronic myelogenous leukemia- initiating cells require polycomb group protein EZH2. Send to 2016 PMID: 27630126

Product Documents for JQEZ5